Literature DB >> 2192281

Prion diseases of the central nervous system.

S B Prusiner, S J DeArmond.   

Abstract

Prions are novel, transmissible pathogens causing degenerative diseases in humans and animals. Kuru, CJD, and GSS illustrate the infectious, sporadic, and genetic mechanisms for human prion diseases, respectively. Scrapie of sheep and goats is the prototypic prion disorder since it was the first of these diseases to be transmitted to laboratory rodents. Over the past five years, a large amount of experimental data about the particles causing scrapie has been accumulated. Most of the information has been confirmed, and much of it is widely accepted. At times, this confirmed body of information has been overshadowed by what appears to be controversy due to the diverse terminology used by different laboratories. Prions are composed largely, if not entirely, of an abnormal isoform of the prion protein (PrP). The development of procedures to disperse infectious prions in detergent-lipid-protein complexes (DLPC) and liposomes has led to many advances. Previously, purified prions were aggregated into rod-shaped particles which are insoluble amyloids. Monoclonal antibodies (mAb) raised against PrP 27-30, which is derived from the scrapie PrP isoform (PrPSc) by limited proteolysis. have been used to purify scrapie prion infectivity in DLPC. Immunoaffinity purified fractions contain PrPSc and high prion titers. Polyclonal antibodies to PrP 27-30 were found to neutralize scrapie infectivity. These experimental results coupled with additional biochemical, genetic, pathologic, and cell biological lines of evidence have established that PrPSc is a major and necessary component of the scrapie prion. Both PrPSc and its cellular isoform (PrPc) are encoded by the same single-copy chromosomal gene. This is a major feature distinguishing prions from both viruses and viroids. To date, no prion-specific nucleic acid has been identified that is required for transmission of disease. PrPC and PrPSc are thought to have the same amino acid sequence but to differ due to some posttranslational process. Both PrPC and PrPSc are glycoproteins that possess Asn-linked oligosaccharides and glycosyl phosphatidylinositol (GPI) anchors. Whether the features that distinguish PrPSc from PrPC arise from differences in their Asn-linked oligosaccharides or GPI anchors is unknown. GSS and familial CJD are the only known human diseases that are both genetic and infectious. Recent studies have demonstrated that GSS is an autosomal dominant disorder and that a Pro----Leu substitution at codon 102 of the PrP gene is linked to the development of GSS. Earlier investigations showed genetic linkage between an incubation time gene (Prn-i) and the PrP gene in inbred mice.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2192281

Source DB:  PubMed          Journal:  Monogr Pathol        ISSN: 0077-0922


  5 in total

1.  High pressure, a tool to switch between soluble and fibrillar prion protein structures.

Authors:  Joan Torrent; Reinhard Lange
Journal:  Commun Integr Biol       Date:  2012-01-01

2.  Infectious prion protein alters manganese transport and neurotoxicity in a cell culture model of prion disease.

Authors:  Dustin P Martin; Vellareddy Anantharam; Huajun Jin; Travis Witte; Robert Houk; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Neurotoxicology       Date:  2011-08-19       Impact factor: 4.294

3.  18F-fluorodeoxyglucose-PET and 99mTc-bicisate-SPECT in Creutzfeldt-Jakob disease.

Authors:  F Grünwald; C Pohl; H Bender; A Hartmann; C Menzel; J Ruhlmann; E Keller; H J Biersack
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

4.  Downregulated PRNP Facilitates Cell Proliferation and Invasion and Has Effect on the Immune Regulation in Ovarian Cancer.

Authors:  Kuan Hu; Xiaofang Zhang; Lei Zhou; Juanni Li
Journal:  J Immunol Res       Date:  2022-09-29       Impact factor: 4.493

5.  MGr1-Antigen/37 kDa laminin receptor precursor promotes cellular prion protein induced multi-drug-resistance of gastric cancer.

Authors:  Guanhong Luo; Weijie Wang; Qiong Wu; Yuanyuan Lu; Tao Su; Nan Gu; Kai Li; Jingbo Wang; Rui Du; Xiaodi Zhao; Xiaohua Li; Rui Fan; Hongbo Zhang; Yongzhan Nie; Xinmin Zhou; Yongquan Shi; Jie Liang; Xin Wang; Daiming Fan
Journal:  Oncotarget       Date:  2017-05-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.